Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated. ## Methods: We studied MH during long-term treatment with IFX in 214 CD patients. A total of 183 patients
Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab
✍ Scribed by D. Laharie; A. Reffet; G. Belleannée; E. Chabrun; C. Subtil; S. Razaire; M. Capdepont; V. de Lédinghen
- Book ID
- 108606192
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 195 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0269-2813
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background: Infliximab is the only medical therapy that has been proven to be effective in fistulizing Crohn's disease (CD), but the recurrence rate of fistulas is high despite maintenance therapy. The aim of this prospective study was to evaluate the short-and long-term efficacy of a combined sched
## Background: There are no studies assessing mucosal healing of the small bowel in patients with Crohn's disease (CD). Our aim was to assess the correlation between clinical response and mucosal healing of the small bowel using wireless capsule endoscopy (WCE). ## Methods: This was a prospecti